← Back to Screener
Theriva Biologics, Inc. (TOVX)
Price$0.41
Favorite Metrics
Price vs S&P 500 (26W)-53.28%
Price vs S&P 500 (4W)23.29%
Market Capitalization$18.89M
All Metrics
Book Value / Share (Quarterly)$0.43
P/TBV (Annual)2.85x
Cash Flow / Share (Quarterly)$-0.47
Price vs S&P 500 (YTD)18.11%
Gross Margin (TTM)71.52%
Net Profit Margin (TTM)-54.11%
EPS (TTM)$-4.01
10-Day Avg Trading Volume15.19M
EPS Excl Extra (TTM)$-4.01
EPS (Annual)$-1.96
ROI (Annual)-138.74%
Gross Margin (Annual)-20.00%
Net Profit Margin (5Y Avg)-18442.92%
Cash / Share (Quarterly)$0.37
ROA (Last FY)-62.08%
EBITD / Share (TTM)$-1.98
ROE (5Y Avg)-78.60%
Operating Margin (TTM)-54.11%
Cash Flow / Share (Annual)$-0.47
P/B Ratio1.23x
P/B Ratio (Quarterly)0.46x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-32.17x
ROA (TTM)-69.28%
EPS Incl Extra (Annual)$-1.96
Current Ratio (Annual)1.74x
Quick Ratio (Quarterly)1.64x
3-Month Avg Trading Volume12.36M
52-Week Price Return-80.52%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.61
P/S Ratio (Annual)7.24x
Asset Turnover (Annual)0.64x
52-Week High$1.50
Operating Margin (5Y Avg)-17385.37%
EPS Excl Extra (Annual)$-1.96
CapEx CAGR (5Y)28.47%
Tangible BV CAGR (5Y)35.96%
26-Week Price Return-44.53%
Quick Ratio (Annual)1.64x
13-Week Price Return28.15%
Total Debt / Equity (Annual)0.11x
Current Ratio (Quarterly)1.74x
Enterprise Value$7.561
Asset Turnover (TTM)0.76x
Book Value / Share Growth (5Y)-33.97%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-45.98%
Cash / Share (Annual)$0.37
3-Month Return Std Dev106.68%
Net Income / Employee (TTM)$-2
ROE (Last FY)-154.32%
Net Interest Coverage (Annual)-212.50x
EPS Basic Excl Extra (Annual)$-1.96
Receivables Turnover (TTM)17.08x
Total Debt / Equity (Quarterly)0.11x
EPS Incl Extra (TTM)$-4.01
Receivables Turnover (Annual)0.00x
ROI (TTM)-172.87%
P/S Ratio (TTM)5.98x
Pretax Margin (5Y Avg)-18439.01%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.61
Price vs S&P 500 (52W)-115.61%
Year-to-Date Return22.24%
5-Day Price Return1.62%
EPS Normalized (Annual)$-1.96
ROA (5Y Avg)-43.11%
Net Profit Margin (Annual)-65.52%
Month-to-Date Return31.36%
Cash Flow / Share (TTM)$-1.16
EBITD / Share (Annual)$-1.97
Operating Margin (Annual)-45.98%
LT Debt / Equity (Annual)0.11x
ROI (5Y Avg)-75.18%
LT Debt / Equity (Quarterly)0.11x
EPS Basic Excl Extra (TTM)$-4.01
P/TBV (Quarterly)2.85x
P/B Ratio (Annual)0.46x
Pretax Margin (TTM)-54.11%
Book Value / Share (Annual)$0.43
Price vs S&P 500 (13W)25.29%
Beta0.75x
Revenue / Share (TTM)$0.00
ROE (TTM)-196.84%
52-Week Low$0.16
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.13
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TOVXTheriva Biologics, Inc. | 5.98x | — | 71.52% | — | $0.41 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Theriva Biologics is a clinical-stage biopharmaceutical company developing oncolytic adenovirus therapies for cancers with significant unmet medical needs. Its lead program, VCN-01, breaks down tumor stroma to enhance viral penetration, while preclinical program VCN-11 employs proprietary Albumin Shield Technology to protect oncolytic viruses from immune system inactivation during systemic delivery.